Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".
Piorkowski
Joseph D
JD
Law Office of Joseph D. Piorkowski Jr, and Georgetown University Law Center, Washington, DC, USA. JPiorkowski@lawdoc1.com
D016907:Adverse Drug Reaction Reporting Systems; D016265:Conflict of Interest / Q000331:legislation & jurisprudence; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000331:legislation & jurisprudence; D004347:Drug Interactions; D004348:Drug Labeling; D005104:Expert Testimony; D015248:Gemfibrozil / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D016365:Liability, Legal; D011725:Pyridines / Q000009:adverse effects*; D012206:Rhabdomyolysis / Q000139:chemically induced*; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011725:Pyridines; C086276:cerivastatin; D015248:Gemfibrozil